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Abstract
Background: Costimulatory signaling has been implicated as a potential regulator of antitumor
immunity in various human cancers. In contrast to the negative prognostic value of aberrant B7-H1
expression by pancreatic cancer cells, the role of B7-H3 is still unknown. Therefore, we
investigated the expression pattern and clinical significance of B7-H3 expression in human
pancreatic cancer.
Methods:  B7-H3 expression was evaluated by immunohistochemistry in 68 patients with
pancreatic cancer who underwent surgical tumor resection. Expression data was correlated with
clinicopathologic features and with the number of tumor-infiltrating T cells.
Results: B7-H3 expression was significantly upregulated in pancreatic cancer compared to normal
pancreas (p < 0.05). In 60 of 68 examined tumors B7-H3 protein was detectable in pancreatic
cancer cells. Patients with high tumor B7-H3 levels had a significantly better postoperative
prognosis than patients with low tumor B7-H3 levels (p = 0.0067). Furthermore, tumor B7-H3
expression significantly correlated with the number of tumor-infiltrating CD8+ T cells (p = 0.018).
Conclusion: We demonstrate for the first time that B7-H3 is abundantly expressed in pancreatic
cancer and that tumor-associated B7-H3 expression significantly correlates with prolonged
postoperative survival. Our findings suggest that B7-H3 might play an important role as a potential
stimulator of antitumor immune response in pancreatic cancer.
Background
Pancreatic cancer is one of the most devastating human
malignancies. At present, pancreatic cancer is the fourth
leading cause of cancer-related deaths in the U.S. [1].
Despite great efforts on clinical and molecular pancreatic
cancer research, the prognosis remains poor with an over-
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all 5-year-survival of less than 5% [2]. Complete surgical
resection still represents the only potentially curative
treatment [3]. By the time of diagnosis, however, only few
patients are candidates for surgery.
The capability to modulate or even suppress antitumor
immune responses is a characteristic feature enabling
malignant tumors to evade immune surveillance and sub-
sequent destruction [4-6]. Costimulatory signaling plays a
key role in the initiation and termination of immune
responses by regulation of T cell priming, growth, matura-
tion, and tolerance [7]. One of the best characterized cos-
timulatory pathways includes B7-1/B7-2:CD28 signaling
[7]. Engagement of B7-1 on antigen-presenting cells with
CD28 on T cells enhances T cell proliferation and IL-2
production. In the absence of this simultaneous costimu-
latory signal, ligation of the T cell receptor by an antigenic
peptide results in T cell dysfunction, intolerance or anergy
[7]. Beside positive costimulatory signals that augment
and sustain T cell response, costimulatory pathways also
deliver inhibitory signals which downregulate T cell
response. Binding of CTLA-4 to B7-1 and/or B7-2 has
been shown to inhibit IL-2 synthesis and progression
through the cell cycle leading to the termination of T cell
response [7,8].
Within the past decade, new costimulatory ligands and
receptors have been identified including B7-H1 (pro-
grammed death-1 ligand-1), B7-DC (programmed death-
1 ligand-2), PD-1 (programmed death-1), B7-H3, and B7-
H4 [9,10]. In contrast to the well-defined roles of B7-1
and B7-2 as essential costimulators involved in T cell acti-
vation, the function of B7-H1, B7-DC, B7-H3, and B7-H4
is less clear. Recently, B7 homologues have been impli-
cated as potential regulators of antitumor immunity [4].
Numerous human cancers have been reported to aber-
rantly express B7-H1 [11-14]. Aberrant B7-H1 expression
by tumor cells has been associated with adverse patho-
logic features and poor outcome [15,16]. We and others
have previously shown that pancreatic cancer patients
with cancer-cell associated B7-H1 expression had a signif-
icantly poorer prognosis than patients with B7-H1 nega-
tive tumors [12,13]. Thus, aberrant expression of B7-H1
has been postulated as a potential mechanism by which
malignant tumors may evade the host immune response.
A possible explanation for the tumor-associated immune
suppression is that aberrant expression of B7-H1 might
downregulate tumor-specific T cell response by inducing
T cell anergy or apoptosis.
In contrast to the negative prognostic value of aberrant
B7-H1 expression by tumor cells, the role of B7-H3 in
human cancers is controversial. B7-H3 is a B7 homologue
that shares approximately 25% sequence homology with
B7-H1. In contrast to B7-H3 mRNA, which is broadly
expressed in lymphoid and non-lymphoid organs, B7-H3
protein expression seems to be limited. Functionally, B7-
H3 is thought to serve as an accessory costimulatory regu-
lator of T cell responses following initial T cell priming.
However, its exact physiologic role is still unclear, because
both stimulatory and inhibitory properties have been
described. Initially, it has been reported that human B7-
H3 costimulates proliferation of both CD4+ and CD8+ T
cells, enhances the induction of cytotoxic T cells, and
selectively stimulates IFN-γ production in the presence of
T cell receptor signaling [17]. In mice, however, B7-H3
inhibits proliferation of both CD4+ and CD8+ T cells and
IFN-γ production [18]. In accordance to its inconsistent
immunologic function, the role of B7-H3 in cancer
remains far from clear. For example, transfection of B7-H3
into P815 tumor cells led to the regression of tumors and
amplification of a tumor-specific CD8+ cytotoxic lym-
phocyte response in syngeneic mice [19]. In another
experimental study, adenoviral B7-H3 treatment resulted
in a reduction of tumor size and a significant reduction of
secondary metastases in an orthotopic murine colon can-
cer model [20]. In a model of EL-4 lymphoma, injection
of a B7-H3 expression plasmid into the tumor resulted in
complete regression of 50% of tumors [21]. The response
depended upon CD8+ T cells and NK cells [21]. In con-
trast to these tumor-protective effects of B7-H3, tumor B7-
H3 expression in human non-small-cell lung cancer
inversely correlated with the number of tumor-infiltrating
lymphocytes and significantly correlated with lymph
node metastases [22]. In prostate cancer, two studies ana-
lyzing B7-H3 expression in a considerable number of
patients revealed that almost all examined tumors
expressed B7-H3 protein. Both studies showed a signifi-
cant correlation between high B7-H3 expression by tumor
cells and disease spread and poor outcome [23,24].
Here, we show for the first time that B7-H3 is abundantly
expressed in pancreatic cancer and that B7-H3 expression
by pancreatic cancer cells correlates with increased patient
survival as well as with the number of tumor-infiltrating
CD8+ T cells.
Methods
Patients
All tissue specimens analyzed in this study were obtained
according to institutional review board-approved proce-
dures for consent. Human pancreatic cancer tissue sam-
ples were obtained from 96 patients (39 female and 57
male patients with a median age of 63 years; age range, 38-
83 years), who underwent resection for pancreatic cancer
at the University Hospital of Heidelberg (Heidelberg, Ger-
many) between 2001 and 2006. Two patients presented
with stage IB, 11 patients presented with stage IIA disease,
70 patients presented with stage IIB disease, two patients
presented with stage III disease, and 11 patients presentedBMC Cancer 2009, 9:463 http://www.biomedcentral.com/1471-2407/9/463
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with stage IV disease according to the UICC classification
(6th edition, 2002). The median follow-up was 23
months, with a range from 2 to 44 months. Normal
human pancreatic tissue samples were obtained through
an organ donor program from 10 previously healthy indi-
viduals (four female, six male; median age of 43 years,
with a range of 17-62 years) when there was no suitable
recipient.
Tissue Sampling
Immediately after surgical removal, tissue samples were
either snap-frozen in liquid nitrogen (for RNA and pro-
tein extraction) or fixed in 10% buffered formalin solu-
tion and embedded in paraffin for histological analysis. A
serial section of each specimen was stained with H&E for
histological evaluation. In addition, a portion of the tissue
specimen was preserved in RNAlater (Ambion Europe
Ltd., Huntington, Ambridgeshire, UK).
Cell culture
Panc-1, MiaPaCa-2 and SU86.86 pancreatic cancer cells
were grown routinely in RPMI 1640 with L-glutamine and
25 mM HEPES (Gibco, Karlsruhe, Germany) supple-
mented with 10% fetal bovine serum (FBS), 100 U/ml
penicillin, and 100 μg/ml streptomycin (Invitrogen, Karl-
sruhe, Germany) and incubated in a 5% CO2 humidified
atmosphere.
Quantitative RT-PCR
All reagents and equipment for mRNA/cDNA preparation
were purchased from Roche Applied Science (Mannheim,
Germany). Messenger-RNA was prepared by automated
isolation using MagNA Pure LC instrument and isolation
kits I (for cells) and II (for tissues). Complementary-DNA
was prepared using the First Strand cDNA Synthesis Kit for
reverse transcription-PCR according to the manufacturer's
instructions. Real-time PCR was performed with the Light-
CyclerFastStart DNA SYBR Green kit as described previ-
ously [25]. B7-H3, CD4, CD8, and IFN-γ primers were
obtained from Search-LC (Heidelberg, Germany). The
number of specific transcripts was normalized to the aver-
age expression of two housekeeping genes (cyclophillin B
and hypoxanthine-guanine phosphoribosyltransferase)
[25]. The data of two independent analyses for each sam-
ple and parameter were averaged and presented as
adjusted transcripts/μl cDNA.
Antibodies/Immunohistochemistry
Immunohistochemical analyses were carried out with
mouse anti-human B7-H3 antibody (MAB 1027, R&D
Systems, Minneapolis, MN), mouse anti-human CD4
antibody (1F6, Monosan, Uden, Netherlands), and
mouse anti-human CD8 antibody (DAKO Diagnostics
AG, Zürich, Switzerland). Antigen retrieval was achieved
by microwave pre-treatment in citrate buffer. Paraffin-
embedded pancreatic tissue sections (3-μm thick) were
deparaffinized with xylene and rehydrated through
graded alcohol into distilled water. After washing in Tris-
buffered saline, endogenous peroxidase activity was
quenched by incubating the slides in 3% hydrogen perox-
ide in methanol. To block unspecific activity of secondary
antibodies, slides were treated with TBS/3%BSA. After
overnight incubation at 4°C with the primary antibody,
slides were washed with Tris-buffered saline and 0.05%
Tween 20, treated with anti-mouse (DAKO) horseradish
peroxidase-labeled secondary antibody for 1 hour, devel-
oped using Dako Envision System (DAKO), and counter-
stained with Mayer's hematoxylin. To ensure antibody
specificity, negative control slides were incubated with
normal mouse IgG. Immunohistochemistry results were
evaluated by scanning each slide under low power magni-
fication (×10) to identify regions containing positive
immunoreactivity. Immunostaining was further evalu-
ated at high power magnification (×200). Tumor samples
were examined by two observers in a blind manner.
Semi-quantitative analysis of B7-H3 expression in tissues 
and its correlation with patient survival
To assess the impact of B7-H3 protein expression by can-
cer cells on patient survival, tissue blocks of 68 histologi-
cally confirmed pancreatic cancer patients were analyzed
by immunohistochemistry. Evaluation of B7-H3 staining
in cancer cells was made semi-quantitatively as published
by Erkan M and co-workers [25]. Scores were given sepa-
rately for the stained area and for the intensity of staining.
Quantification was made as follows; ≤33% of the cancer
cells: 1, >33 to ≤66% of the cancer cells: 2, >66% of the
cancer cells: 3; intensity of staining: absent/weak: 1, mod-
erate: 2, strong: 3. Each section had a final grade that
derived from the multiplication of the area and intensity
scores. Sections with a final score of ≤3 were classified as
tumors with low B7-H3 expression, whereas sections with
a final score of > 3 were classified as tumors with high B7-
H3 expression.
Semi-quantitative evaluation of the prevalence of tumor-
infiltrating CD4+ and CD8+ T cells in pancreatic cancer 
tissues and correlation with B7-H3 expression
To examine whether tumor B7-H3 expression is associ-
ated with the infiltration of CD4+ or CD8+ T cells, we
semi-quantitatively evaluated the prevalence of CD4+ and
CD8+ cells in pancreatic cancer specimens. Consecutive
slides from the same tumor were stained for CD4, CD8,
and B7-H3. Using histological landmarks, corresponding
areas with tumor B7-H3 and without tumor B7-H3
expression were identified under low power magnifica-
tion (×10). The prevalence of CD4+ or CD8+ T cells was
semi-quantitatively evaluated at high power magnifica-
tion (×400) according to the number of CD4 positive or
CD8 positive cells per areas: Areas with 0-5 CD4 positiveBMC Cancer 2009, 9:463 http://www.biomedcentral.com/1471-2407/9/463
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or CD8 positive cells were recorded as (0), areas with 6-15
CD4 positive or CD8 positive cells were recorded as (1),
and areas with >15 CD4 positive or CD8 positive cells
were recorded as (2). Tumor samples were examined by
two observers in a blind manner.
Induction of B7-H3 in cultured pancreatic cancer cell lines 
and FACS analysis
To determine the effect of IFN-γ (R&D Systems) or IL-4
(R&D Systems) on the expression of B7-H3 in cultured
pancreatic cancer cells, Panc-1, MiaPaCa-2, and SU86.86
cells were seeded in 6-well plates (100,000 cells per well),
and incubated with 2000 IU/ml of recombinant IFN-γ or
40 ng/ml of recombinant IL-4 for 24 or 48 hours. Cells
were harvested and stained with anti-human B7-H3-FITC
mAb (R&D Systems) or control anti-human IgG-FITC (BD
Pharmingen, Heidelberg, Germany). Single-color flow
cytometry was performed by using a FACSCalibur (Bec-
ton-Dickinson, BD) and analyzed with FlowJo Software
(Tree Star).
Statistical Analysis
Results are expressed as mean ± SD (mRNA expression).
For statistical analysis, GraphPad Prism software (Graph-
Pad Software, San Diego, CA) was used. The Mann-Whit-
ney U test, χ2 test or Spearman rho test were performed for
comparative statistical evaluations among groups and for
correlation analysis with histological and clinical parame-
ters (age, gender, tumor stage, tumor grade, and postoper-
ative survival). Significance was defined as p < 0.05. The
Kaplan-Meier method was used to estimate the probabil-
ity of survival, and significance was assessed by the log-
rank test.
Results
Expression of the costimulatory molecule B7-H3 in human 
pancreatic cancer
Quantitative RT-PCR was performed to assess mRNA
expression of the costimulatory molecule B7-H3 in 28
surgically resected human pancreatic cancer tissue speci-
mens and 10 normal human pancreatic tissue specimens.
B7-H3 mRNA was significantly upregulated in pancreatic
cancer tissues (275.5 transcripts ± 44.4) compared to nor-
mal pancreatic tissue samples (86.5 ± 22.2; p < 0.05). To
confirm the qRT-PCR data and to assess the location of
B7-H3 protein, we performed immunostainings of 68
pancreatic cancer tissue samples. In pancreatic cancer tis-
sues, abundant positive B7-H3 immunoreactivity could
be detected in pancreatic cancer cells (Fig. 1), pancreatic
islet cells, tumor-infiltrating immune cells, and sporadical
weak immunoreactivity in tumor-surrounding tubular
complexes and endothelial cells. Among the examined 68
pancreatic cancer tissues, 60 showed positive B7-H3 pro-
tein expression in pancreatic cancer cells. According to the
Immunohistochemical characterization of B7-H3 expression in 4 representative human pancreatic cancer tissue sections Figure 1
Immunohistochemical characterization of B7-H3 expression in 4 representative human pancreatic cancer tis-
sue sections. Positive B7-H3 immunoreactivity was detectable in pancreatic cancer cells (brown staining). Representative tis-
sue sections of strong intensity (A), moderate intensity (B), and weak intensity (C). (D) Negative control.BMC Cancer 2009, 9:463 http://www.biomedcentral.com/1471-2407/9/463
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staining intensity, all specimens were classified into three
groups with either no or weak, moderate or strong immu-
noreactivity (Fig. 1). Depending on the area of positive
immunoreactivity, a final overall score (high tumor B7-
H3 or low tumor B7-H3 expression) was established as
described in the methods section. In normal pancreatic
tissues, weak B7-H3 protein expression could be sporadi-
cally detected in normal pancreatic acinar and ductal cells.
B7-H3 expression correlates with better postoperative 
survival in pancreatic cancer patients
Costimulatory signaling has been implicated as a possible
regulator of antitumor immunity in several human malig-
nancies. We investigated the relationship between tumor-
associated B7-H3 protein expression and various clinico-
pathological features in pancreatic cancer (Table 1). No
correlation could be observed between tumor B7-H3
expression and age, gender, tumor stage, and tumor grade.
In contrast, high tumor B7-H3 expression was associated
with significantly prolonged postoperative survival in
pancreatic cancer patients (p = 0.0067; Fig. 2). Among the
examined 68 pancreatic cancer tissues, 40 showed low
tumor B7-H3 expression, whereas 28 showed high tumor
B7-H3 expression. The median survival in patients with
high tumor B7-H3 expression was 17.8 months and 11.0
months in patients with low B7-H3 expression (Fig. 2).
IFN-γ is upregulated in human pancreatic cancer in vivo 
and significantly correlates with tumor B7-H3 expression
In vitro, B7-H3 has been shown to selectively stimulate
IFN-γ production by purified human T lymphocytes [17].
To examine whether B7-H3 expression is associated with
IFN-γ levels in vivo, we analyzed cytokine gene expression
of B7-H3 and IFN-γ by qRT-PCR in 28 pancreatic cancer
tissue samples and 10 normal pancreatic tissue samples.
Gene expression of IFN-γ was significantly upregulated in
pancreatic cancer tissues in comparison to normal pancre-
atic tissues (p < 0.05; Fig. 3A). Correlation analysis
revealed a statistically significant correlation between B7-
H3 and IFN-γ expression (p = 0.0225; Spearman rho
0.4297; Fig. 3B).
Cultured pancreatic cancer cell lines Panc-1, MiaPaCa-2, 
and SU86.86 constitutively express B7-H3
To test whether pancreatic cancer cells express the costim-
ulatory molecule B7-H3 in vitro, we performed qRT-PCR.
All tested cultured pancreatic cancer cell lines constitu-
tively expressed B7-H3 mRNA under normal conditions
(Panc-1 541 transcripts ± 36.6, MiaPaCa-2 358 transcripts
± 17.5, SU86.86 743 transcripts ± 725).
Treatment of cultured SU86.86 pancreatic cancer cells 
with IFN-γ or IL-4 markedly increases their B7-H3 
expression
To assess the effect of the Th1 and Th2 cytokines IFN-γ and
IL-4 on B7-H3 expression by cultured pancreatic cancer
cells, cells (representative pancreatic cancer cell lines
Panc-1 and SU86.86) were incubated with recombinant
Overall survival of 68 pancreatic cancer patients in relation  with B7-H3 protein expression Figure 2
Overall survival of 68 pancreatic cancer patients in 
relation with B7-H3 protein expression. Patients with 
high tumor B7-H3 protein expression had a significantly bet-
ter prognosis than patients without or with low tumor B7-
H3 protein expression (p = 0.0067). The median survival of 
patients with high tumor B7-H3 protein expression was 17.8 
months in contrast to 11.0 months in patients without or 
with low tumor B7-H3 protein expression.
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Table 1: Clinicopathological characteristics according to tumor 
B7-H3 expression.
B7-H3 expression
Variable n low high p-value
Gender n.s.
Female 24 16 8
Male 44 25 19
Tumor status n.s.
T1 0 0 0
T2 4 3 1
T3 62 36 26
T4 2 1 1
Nodal status n.s.
N0 10 5 5
N1 58 35 23
Metastatic status n.s.
M0 58 35 23
M1 10 4 6
Tumor grade n.s.
G1 2 1 1
G2 44 27 17
G3 22 12 10
G4 0 0 0
Survival (in months) 11 17,8 p = 0.0067BMC Cancer 2009, 9:463 http://www.biomedcentral.com/1471-2407/9/463
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IFN-γ and IL-4 for 24 and 48 hours. Treatment of Panc-1
cells with IFN-γ slightly decreased the expression of B7-H3
after 24 hours. The effect nearly disappeared after 48
hours (Fig. 4A). In SU86.86 cells IFN-γ treatment resulted
in a marked increase of B7-H3 expression after 24 hours
which slightly decreased after 48 hours (Fig. 4B). IL-4
treatment similarly led to a slight decrease of B7-H3
expression in Panc-1 cells after 24 hours which was more
pronounced after 48 hours (Fig. 4C) in contrast to
SU86.86 cells in which IL-4 exposure resulted in a marked
increase after 24 hours with an amplification of B7-H3
expression after 48 hours (Fig. 4D). Thus, in contrast to
Panc-1 cells, treatment with IFN-γ and more pronounced
treatment with IL-4 increased expression of B7-H3 on the
surface of SU86.86 cells.
B7-H3 protein expression correlates with the number of 
CD8+ T cells in human pancreatic cancer tissues
To determine the potential relevance of B7-H3 expression
on the distribution of CD4+ or CD8+ T cells in pancreatic
cancer, we first examined mRNA levels of CD4 and CD8
in 28 pancreatic cancer tissue specimens and 10 normal
pancreatic tissue specimens. Gene expressions were mark-
edly increased in pancreatic cancer tissues compared to
normal pancreatic tissues (CD4: 150 transcripts ± 28.1 in
pancreatic cancer vs. 52 transcripts ± 12.4 in normal pan-
creas; CD8: 171 transcripts ± 30.2 in pancreatic cancer vs.
39 transcripts ± 6.4 in normal pancreas). B7-H3 mRNA
expression significantly correlated with CD4 (p < 0.0001,
Spearman rho 0.76) and CD8 mRNA levels (p < 0.0097,
Spearman rho 0.48). To determine whether the expres-
sion of B7-H3 by pancreatic cancer cells influences the dis-
tribution of tumor-infiltrating CD4+ or CD8+ T cells, we
performed immunohistochemical stainings for B7-H3,
CD4, and CD8 of 20 randomly chosen pancreatic cancer
tissue sections. Immunohistochemistry analysis revealed
a significant correlation between the level of tumor B7-H3
expression and the number of tumor-infiltrating CD8+ T
cells (p = 0.018; Fig. 5 and 6). No correlation could be
observed between the level of tumor B7-H3 expression
and the number of tumor-infiltrating CD4+ T cells.
Discussion
Pancreatic cancer is one of the most aggressive human
malignancies and still represents a major therapeutic chal-
lenge. Despite the infiltration of large numbers of
immune cells into pancreatic cancer, the immune system
fails to prevent disease development and progression.
Recently, dysregulation of immune responses by aberrant
expression of negative costimulatory molecules by tumor
cells has been suggested to play a potential role in the eva-
sion of tumors from the immune system [4,5]. For exam-
ple, tumor B7-H1 expression has been shown to
significantly correlate with negative outcome in several
human malignancies, including pancreatic cancer [11,13-
16]. B7-H3 is another member of the B7 family of costim-
ulatory molecules which serves as an accessory costimula-
tory regulator of T cell responses following initial T cell
priming. The exact physiological function of B7-H3 and
especially its role in the development and progression of
human cancers are still elusive.
In this study, we demonstrated that the cultured pancre-
atic cancer cell lines Panc-1, MiaPaCa-2, and SU86.86
constitutively express B7-H3. Moreover, we demonstrated
that B7-H3 gene expression is upregulated in pancreatic
cancer tissues in comparison to normal pancreatic tissues.
Immunohistochemical analysis revealed B7-H3 protein
expression by pancreatic cancer cells. Tumor cell-associ-
ated B7-H3 expression significantly correlated with better
postoperative survival. Moreover, we showed that B7-H3
IFN-γ mRNA expression in 28 pancreatic cancer tissues and  10 normal pancreatic tissues Figure 3
IFN-γ mRNA expression in 28 pancreatic cancer tis-
sues and 10 normal pancreatic tissues. (A) IFN-γ 
mRNA expression was significantly upregulated in pancreatic 
cancer tissues compared to normal pancreas (p < 0.05). (B) 
Correlation analysis of B7-H3 mRNA and IFN-γ mRNA 
expression in pancreatic cancer (n = 28) revealed a positive 
correlation between B7-H3 and IFN-γ mRNA expression (p 
= 0.0225; Spearman rho 0.4297).
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gene expression in pancreatic cancer tissues significantly
correlated with the levels of CD4 and CD8. Further immu-
nohistochemical analyses on the distribution of CD4+
and CD8+ T cells revealed the infiltration of CD4+ and
CD8+ T cells into areas of B7-H3 positive pancreatic can-
cer cells. More importantly, the number of tumor-infiltrat-
ing CD8+ T cells significantly correlated with the levels of
B7-H3 on pancreatic cancer cells. Therefore, one could
speculate that tumor-associated B7-H3 expression might
act as a positive regulator of antitumor response in pan-
creatic cancer. B7-H3 might trigger the infiltration of
CD8+ T cells into cancerous tissues and might also
enhance tumor immunogenicity by stimulation of tumor-
infiltrating CD8+ T cells. These findings are in accordance
with previous reports on the function of B7-H3. Chapoval
and colleagues reported that human B7-H3 costimulates
proliferation of CD8+ T cells, enhances the induction of
cytotoxic T cells, and selectively stimulates IFN-γ produc-
tion by T cells in the presence of T cell receptor signaling
in vitro [17]. Further data in support of a positive costim-
ulatory role of B7-H3 in the regulation of immune
response come from an experimental study showing that
acute and chronic cardiac allograft rejection can be
reduced in B7-H3 knock-out mice [26]. Recently, B7-H3
has also been implicated as a potential stimulator of anti-
tumor immunity. In vivo, transfection of B7-H3 into P815
mouse tumors led to tumor regression and amplification
of tumor-specific CD8+ CTL response in syngeneic mice
suggesting enhancement of tumor immunogenicity by
preferential stimulation of CD8+ T cell responses [19].
Effects of treatment with IFN-γ or IL-4 on Panc-1 and SU86.86 pancreatic cancer cells Figure 4
Effects of treatment with IFN-γ or IL-4 on Panc-1 and SU86.86 pancreatic cancer cells. Cells were treated with 
either 2000 IU/ml of recombinant IFN-γ or 40 ng/ml of recombinant IL-4 for 24 or 48 hours and analyzed by FACS. (B) IFN-γ 
treatment resulted in a marked increase of B7-H3 expression on SU86.86 cells after 24 hours (green line) and 48 hours (red 
line). (D) IL-4 treatment resulted in a marked increase of B7-H3 expression on SU86.86 cells after 48 hours (red line), but not 
after 24 hours (green line). In contrast, (A) IFN-γ treatment led to a slight decrease of B7-H3 expression on Panc-1 cells 24 
hours after stimulation (green line) with normalization 48 hours after stimulation (red line). (C) IL-4 treatment led to a slight 
decrease of B7-H3 expression on Panc-1 cells 24 hours after stimulation (green line) and 48 hours after stimulation (red line). 
The blue lines display B7-H3 expression without stimulation by IFN-γ and IL-4. The grey lines display the (isotope) control 
group.
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Further evidence in favor of a possible tumor-protective
effect of B7-H3 expression in cancers comes from a clini-
cal study investigating the expression of B7-H3 in human
gastric carcinoma. The majority of tumors showed B7-H3
expression in tumor cells. Moreover, the presence of B7-
H3 positive tumor cells was associated with improved
patient survival [27]. Although these results clearly impli-
cate a tumor-protective effect of B7-H3, the exact physio-
logic/pathologic role of B7-H3 remains ambiguous,
because B7-H3 has also been shown to inhibit CD4+ and
CD8+ T cell proliferation and IFN-γ production mediated
by anti-CD3 in mice [28]. Recently, single or duplicate
constructs of the immunoglobulin-V-like and immu-
noglobulin-C-like domains of B7-H3 have been shown to
downregulate both T cell proliferation and cytokine pro-
duction in response to CD3/CD28-mediated costimula-
tory activation [29]. Further evidence that B7-H3 may
serve as an inhibitor of antitumor immunity includes sev-
eral clinical studies. In prostate cancer, Zang et al. evalu-
ated the expression of B7-H3 in over eight hundred
prostate cancer patients and reported that 93% of the
examined tumors displayed aberrant B7-H3 expression
[23]. High tumor B7-H3 expression was associated with
disease progression and spread as well as with poor
patient survival [23]. Accordingly, tumor cell and tumor
vasculature B7-H3 expression significantly correlated with
an increased risk of death from clear cell renal cell carci-
noma [30]. In these studies, however, the functional
aspect of B7-H3 expression was not tested in detail. For
example, correlation of B7-H3 expression by cancer cells
with tumor-infiltrating immune cells was either not tested
or not significant. The reason for the contrasting effects of
B7-H3 in cancer might also be related to varying counter-
receptors involved in different tumor entities. So far, one
receptor of B7-H3 has been identified [31]. Hashiguchi
and co-workers have recently reported that murine B7-H3
specifically binds to triggering receptor expressed on mye-
loid cells (TREM)-like transcript 2 (TLT-2, TREML2),
which is expressed on both CD4+ and CD8+ T cells [31].
Moreover, the authors demonstrated that stimulation
with B7-H3 transfectants preferentially upregulated the
proliferation and IFN-γ production of CD8+ T cells [31]. In
humans, however, a receptor for B7-H3 has not been
identified yet.
Representative immunohistochemical stainings for B7-H3 (A, C) and CD8 (B, D) in pancreatic cancer tissues Figure 5
Representative immunohistochemical stainings for B7-H3 (A, C) and CD8 (B, D) in pancreatic cancer tissues. 
(A) Pancreatic cancer tissue section with strong B7-H3 immunoreactivity. (B) Consecutive section with immunostaining for 
CD8 shows the infiltration of numerous CD8+ T cells (arrows). (C) Pancreatic cancer tissue section with weak tumor B7-H3 
immunoreactivity. (D) Consecutive section with immunostaining for CD8 shows no CD8+ tumor-infiltrating T cells.
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Another possible mechanism involved in antitumor
immunity includes the induction of tumor-suppressive
cytokines. Here, we found that B7-H3 was significantly
associated with IFN-γ levels. IFN-γ is an important pro-
inflammatory Th1 cytokine and has been implicated as a
mediator of an extrinsic tumor-suppressor mechanism in
immunocompetent hosts. IFN-γ is usually produced by
activated cytotoxic T lymphocytes, macrophages, and nat-
ural killer (NK) cells [32]. In mice, treatment with neutral-
izing monoclonal antibodies to IFN-γ resulted in a faster
growth of immunogenic sarcomas that were transplanted
into mice [33]. Furthermore, endogenously produced
IFN-γ has been shown to be protective against trans-
planted, chemically induced, and spontaneous tumors
[34]. Therefore, B7-H3 might act as an immunostimula-
tory agent through the induction of IFN-γ.
Mechanisms regulating B7-H3 expression are still unclear.
The local cytokine milieu in the tumor microenvironment
represents a potential regulator of B7-H3. Indeed, IFN-γ
has previously been shown to enhance surface expression
of B7-H3 on bone marrow derived dendritic cells and on
monocytes [18]. Therefore, we investigated the potential
effects of the Th1 cytokine IFN-γ and Th2 cytokine IL-4 on
the expression of B7-H3 on cultured pancreatic cancer
cells. We found that both IFN-γ and IL-4 treatment
resulted in a marked increase of B7-H3 on SU86.86 but
not on Panc-1 pancreatic cancer cells. Furthermore, we
found that B7-H3 positively correlated with IFN-γ levels in
vivo. Taken together, these findings suggest a potential
involvement of IFN-γ (and IL-4) in the regulation of B7-
H3 expression in pancreatic cancer.
Conclusion
We demonstrated for the first time that B7-H3 is abun-
dantly expressed in pancreatic cancer and that tumor cell-
associated B7-H3 expression significantly correlates with
prolonged postoperative survival. Moreover, we showed
that B7-H3 expression significantly correlated with the
number of tumor-infiltrating CD8+ T cells. Although fur-
ther functional studies will certainly be required to better
understand the exact role of B7-H3 in pancreatic cancer,
our data suggest that B7-H3 might be involved in the
induction of a specific antitumor immune response and
that treatment with B7-H3 (e.g. by gene transfer) might
represent a promising approach to improve the outcome
of pancreatic cancer patients.
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